{"log_id": 2919784436792926351, "direction": 0, "words_result_num": 34, "words_result": [{"probability": {"variance": 0.000174, "average": 0.995338, "min": 0.930269}, "location": {"width": 561, "top": 216, "height": 35, "left": 246}, "words": "对于未使用完的产品或废弃物,应根据相应的管理办法进行处理"}, {"probability": {"variance": 1.1e-05, "average": 0.997843, "min": 0.989408}, "location": {"width": 234, "top": 308, "height": 28, "left": 211}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 3e-06, "average": 0.997508, "min": 0.995797}, "location": {"width": 43, "top": 360, "height": 24, "left": 206}, "words": "妊娠"}, {"probability": {"variance": 5.6e-05, "average": 0.997007, "min": 0.962663}, "location": {"width": 719, "top": 382, "height": 35, "left": 286}, "words": "尚未获得有关帕立骨化醇在妊娠妇女中应用的充足数据。动物研究中已经显示了生"}, {"probability": {"variance": 4.1e-05, "average": 0.997132, "min": 0.962377}, "location": {"width": 801, "top": 415, "height": 39, "left": 205}, "words": "殖毒性(参见【药理毒理】)。对于人类的潜在风险尚不明确。除非有明确的必要性,否则"}, {"probability": {"variance": 6.4e-05, "average": 0.996826, "min": 0.972952}, "location": {"width": 204, "top": 459, "height": 29, "left": 207}, "words": "本品不应用于妊娠妇女"}, {"probability": {"variance": 0.01621, "average": 0.826856, "min": 0.697501}, "location": {"width": 93, "top": 479, "height": 24, "left": 936}, "words": " CO. LTD"}, {"probability": {"variance": 3e-06, "average": 0.998658, "min": 0.996418}, "location": {"width": 67, "top": 521, "height": 26, "left": 206}, "words": "哺乳期"}, {"probability": {"variance": 0.006848, "average": 0.917274, "min": 0.804148}, "location": {"width": 82, "top": 506, "height": 38, "left": 937}, "words": "限公司"}, {"probability": {"variance": 6.9e-05, "average": 0.995632, "min": 0.960165}, "location": {"width": 730, "top": 549, "height": 37, "left": 277}, "words": "动物研究结果显示少量帕立骨化醇或其代谢产物经乳汁排泄。应综合考虑哺乳对儿"}, {"probability": {"variance": 0.004715, "average": 0.980396, "min": 0.593025}, "location": {"width": 892, "top": 580, "height": 48, "left": 207}, "words": "童的益处以及帕立骨化醇治疗对妇女的益处以决定是否继续停止哺乳,或继续/停止帕立骨"}, {"probability": {"variance": 0, "average": 0.99984, "min": 0.999668}, "location": {"width": 80, "top": 638, "height": 23, "left": 209}, "words": "化醇治疗"}, {"probability": {"variance": 0.082529, "average": 0.405801, "min": 0.118522}, "location": {"width": 106, "top": 656, "height": 35, "left": 930}, "words": " QOHD Ye"}, {"probability": {"variance": 1e-06, "average": 0.999165, "min": 0.996704}, "location": {"width": 110, "top": 698, "height": 24, "left": 220}, "words": "【儿童用药】"}, {"probability": {"variance": 7e-06, "average": 0.998636, "min": 0.987692}, "location": {"width": 441, "top": 729, "height": 33, "left": 283}, "words": "中国儿童患者使用本品的安全性和有效性尚未确立"}, {"probability": {"variance": 1e-06, "average": 0.999034, "min": 0.997077}, "location": {"width": 113, "top": 797, "height": 26, "left": 216}, "words": "【老年用药】"}, {"probability": {"variance": 0.000113, "average": 0.994654, "min": 0.965343}, "location": {"width": 175, "top": 835, "height": 26, "left": 282}, "words": "参见【用法用量】。"}, {"probability": {"variance": 7e-06, "average": 0.997438, "min": 0.992428}, "location": {"width": 153, "top": 896, "height": 29, "left": 219}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.00018, "average": 0.995828, "min": 0.919357}, "location": {"width": 725, "top": 933, "height": 36, "left": 284}, "words": "目前尚未对帕立骨化醇注射液进行过药物相互作用的研究。不过,对本品的胶囊制"}, {"probability": {"variance": 1.1e-05, "average": 0.997148, "min": 0.989676}, "location": {"width": 403, "top": 973, "height": 32, "left": 212}, "words": "剂进行过酮康唑与帕立骨化醇的相互作用研究"}, {"probability": {"variance": 0.000625, "average": 0.993744, "min": 0.846003}, "location": {"width": 729, "top": 1014, "height": 37, "left": 284}, "words": "由于高钙血症和钙磷乘积增高的发生风险可能会增高,磷或维生素D类药物不应与帕"}, {"probability": {"variance": 1.2e-05, "average": 0.996014, "min": 0.988659}, "location": {"width": 126, "top": 1060, "height": 25, "left": 214}, "words": "立骨化醇合用"}, {"probability": {"variance": 1.2e-05, "average": 0.997504, "min": 0.988162}, "location": {"width": 540, "top": 1098, "height": 33, "left": 285}, "words": "高剂量的含钙制剂或噻嗪类利尿剂可能会增加高钙血症的风险"}, {"probability": {"variance": 1.7e-05, "average": 0.997573, "min": 0.98111}, "location": {"width": 721, "top": 1141, "height": 37, "left": 285}, "words": "由于可能会出现血铝水平增高和铝相关的骨毒性,含铝制剂(如抗酸剂,磷结合剂)"}, {"probability": {"variance": 1.1e-05, "average": 0.997724, "min": 0.988924}, "location": {"width": 278, "top": 1182, "height": 32, "left": 217}, "words": "不应与维生素D类药物长期联用"}, {"probability": {"variance": 3e-05, "average": 0.997078, "min": 0.977359}, "location": {"width": 694, "top": 1222, "height": 35, "left": 286}, "words": "由于可能会发生高镁血症,含镁的制剂(如抗酸剂)不应与维生素D类药物合用"}, {"probability": {"variance": 0.000423, "average": 0.993948, "min": 0.871166}, "location": {"width": 734, "top": 1268, "height": 35, "left": 287}, "words": "酮康唑是一种已知的针对数种细胞色素P450酶的非特异性抑制剂。现有的体内和体"}, {"probability": {"variance": 8.9e-05, "average": 0.995991, "min": 0.957622}, "location": {"width": 807, "top": 1302, "height": 39, "left": 217}, "words": "外数据提示酮康唑可能与一些参与帕立骨化醇和其它维生素D类似物的代谢的酶之间存在相"}, {"probability": {"variance": 0.000328, "average": 0.995385, "min": 0.883548}, "location": {"width": 805, "top": 1337, "height": 38, "left": 218}, "words": "互作用。因此,在帕立骨化醇给药期间应慎用酮康唑(参见【注意事项】)。在健康受试者"}, {"probability": {"variance": 0.003864, "average": 0.986211, "min": 0.583627}, "location": {"width": 808, "top": 1373, "height": 38, "left": 218}, "words": "中进行了为期5天、每天两次(BID)、每次200mg的多剂量的酮康唑对帕立骨化醇胶囊药代"}, {"probability": {"variance": 0.002278, "average": 0.989007, "min": 0.686959}, "location": {"width": 803, "top": 1407, "height": 38, "left": 219}, "words": "动力学影响的研究。在使用酮康唑的情况下,帕立骨化醇的Cmax几乎不受影响,但AUC约"}, {"probability": {"variance": 0.000435, "average": 0.994671, "min": 0.862684}, "location": {"width": 804, "top": 1442, "height": 38, "left": 219}, "words": "增加了一倍。在使用酮康唑的情况下,帕立骨化醇的平均半衰期为17.0小时,而单独给予帕"}, {"probability": {"variance": 0.004307, "average": 0.982331, "min": 0.640536}, "location": {"width": 806, "top": 1476, "height": 38, "left": 219}, "words": "立骨化醇时则为9.8小时。这项研究结果显示,口服帕立骨化醇之后,由帕立骨化醇与酮康唑"}, {"probability": {"variance": 0.010102, "average": 0.975195, "min": 0.439268}, "location": {"width": 574, "top": 1514, "height": 35, "left": 221}, "words": "药物相互作用导致的帕立骨化醇AUC最大增幅不太可能超过两倍"}], "language": 3}